Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has awarded Columbia University an Agilent Research Catalyst (ARC) Award for Dr. Pawel Muranski's groundbreaking work in cellular immunotherapy. Dr. Muranski, Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center, is developing a novel cGMP platform for generating clinical-grade multi-specific CD4+ cytotoxic T cells to treat various cancers.
The award includes research funding and advanced Agilent instruments including a Seahorse XF Pro Analyzer, xCELLigence RTCA MP instrument, NovoCyte Penteon Flow Cytometer, BioTek Cytation 1 Cell Imaging Reader, and BioTek 800 TS Absorbance Reader. These tools will help accelerate the development of innovative manufacturing methods and establish standardized quality control assays for anti-cancer T cell production.
Agilent Technologies (NYSE: A) has received EU IVDR certification for two new companion diagnostic indications for its PD-L1 IHC 28-8 pharmDx kit, bringing the total European indications to nine. The approvals expand treatment eligibility for:
1. Early-stage non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥1% at high recurrence risk, enabling treatment with OPDIVO® plus platinum-based chemotherapy
2. Previously untreated advanced melanoma patients (12+ years) with tumor cell PD-L1 expression 1%, enabling treatment with Opdualag™The kit, exclusively used with Agilent's Autostainer Link 48, addresses significant healthcare concerns: lung cancer (2+ million new cases, 1.77 million deaths annually) and melanoma (324,000+ new cases, 57,000+ deaths annually). As the only clinically validated test for these treatments, it aids pathologists and oncologists in treatment selection.
Agilent Technologies (NYSE: A) has announced its participation in TD Cowen's 45th Annual Health Care Conference. CEO Padraig McDonnell and CFO Bob McMahon will engage in a fireside chat scheduled for March 4, 2025, from 9:50-10:20 a.m. Eastern in Boston, Massachusetts.
The company will provide a live audio webcast of the presentation, which will also be available for replay through the Agilent Investor Relations website.
Agilent Technologies (NYSE: A) reported Q1 FY2025 results with revenue of $1.68 billion, showing growth of 1.4% reported and 1.2% core compared to Q1 2024. GAAP net income was $318 million ($1.11 per share), down from $348 million ($1.18 per share) in Q1 2024. Non-GAAP net income was $377 million ($1.31 per share), compared to $380 million ($1.29 per share) year-over-year.
By segment, Life Sciences and Diagnostics Markets Group revenue grew 4% reported to $647 million, Agilent CrossLab Group increased 1% to $696 million, while Applied Markets Group declined 4% to $338 million.
For FY2025, Agilent projects revenue of $6.68-6.76 billion (2.6-3.8% growth) and non-GAAP EPS of $5.54-5.61. Q2 outlook expects revenue of $1.61-1.65 billion with non-GAAP EPS of $1.25-1.28.
Agilent Technologies, listed on the NYSE under the ticker A, has declared a quarterly cash dividend of 24.8 cents per share of common stock.
The dividend will be paid on April 23, 2025, to all shareholders who are on record as of the close of business on April 1, 2025.
Future dividend amounts and their timing will be determined and approved by Agilent's board of directors.
Agilent Technologies (NYSE: A) has announced it will release its first-quarter fiscal 2025 financial results after market close on Wednesday, February 26. The company will host a conference call at 1:30 p.m. PST to discuss the results. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website. A recording of the call will remain available on the website for 90 days.
Agilent Technologies (NYSE: A) will showcase new automated laboratory workflow solutions at SLAS2025 International Conference & Exhibition in San Diego from January 25-29. The company is focusing on advancing automation solutions to optimize lab performance, efficiency, and reproducibility across research, drug discovery, development, and manufacturing processes.
The automation solutions cover sample preparation, auto dilution, sample delivery, and washout across various applications including cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry. Key innovations to be showcased include the NovoCyte Opteon Spectral Flow Cytometer, SureSelect Cancer CGP Assay, ePrep Partnership for GC/MS and LC/MS analyses, and Avida for DNA sequencing.
The company will participate in a Solutions Spotlight Presentation on viral infectivity assays and a roundtable discussion about robotic automation in future laboratories. Agilent serves as a Diamond Sponsor of the event.
Agilent Technologies (NYSE: A) has awarded the Solutions Innovation Research Awards (SIRA) to Professors Anders Bentien, Walter Gössler, and Gregory Offer for their significant contributions to battery research.
Professor Bentien of Aarhus University will use the Agilent 5900 ICP-OES for his work on flow battery systems. Professor Gössler from the University of Graz will enhance lithium-ion battery recycling using the Agilent 8900 Triple Quadrupole ICP-MS. Professor Offer at Imperial College London will study lithium-ion battery degradation with the Agilent 5977C GC/MSD.
These awards aim to support innovative research in battery technology, focusing on new materials, recycling, and degradation processes. Agilent's initiative aligns with the need for sustainable energy solutions and aims to empower researchers with advanced analytical tools.
Agilent's SIRA program, established in 2023, supports university research in advanced materials and energy markets, providing state-of-the-art products and expertise to solve critical scientific problems.
Agilent Technologies (NYSE: A) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Padraig McDonnell and CFO Bob McMahon will deliver a presentation on Tuesday, January 14, 2025, at 9:45 a.m. Pacific time. Investors and interested parties can access both the live audio webcast and a replay of the presentation through the Agilent Investor Relations website.
Agilent Technologies (NYSE: A) has received Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx assay in Europe. The assay, which works exclusively with Agilent's Autostainer Link 48 staining solution, helps identify PD-L1 expression, a important biomarker for response to anti-PD-1 antibody therapies like OPDIVO® and OpdualagTM.
The certification covers nine cancer indications, including five companion diagnostic indications: non-small cell lung cancer, muscle invasive urothelial carcinoma, melanoma, esophageal squamous cell carcinoma, and gastric/gastroesophageal junction/esophageal adenocarcinoma. This certification ensures continued uninterrupted access for EU laboratories using Agilent's diagnostic products.